Bedrijfsoverzicht
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm focused on the development and commercialization of products designed to detect microbial contamination within manufacturing processes for pharmaceuticals, biologics, medical devices, and personal care items. The company serves a global footprint with operational reach extending across the United States, Switzerland, Germany, Japan, and various international markets, addressing critical quality control needs in highly regulated industries. Operating within the Healthcare sector specifically under the Medical Devices industry classification, the firm targets entities where sterility assurance is paramount to patient safety and product efficacy. Based on available data, the company's total market capitalization stands at $97.03M, while its trailing twelve-month revenue generation amounts to $33.59M supported by a workforce of 171 employees. These financial metrics indicate that Rapid Micro Biosystems functions as a small-cap entity with a market valuation that is significant relative to its annual sales volume, suggesting a business model where revenue multiples play a crucial role in determining enterprise value rather than traditional earnings-based metrics.
Financiële gezondheid
The company reported trailing twelve-month revenue of $33.59M, yet this top-line activity resulted in a net income loss of $-47,123,000 and an EBITDA of $-44,640,000. The substantial disparity between the $33.59M revenue and the negative net income reveals a highly aggressive cost structure or significant one-time expenses that erode profitability at a rate of over 140% of revenue. Additionally, the business generated free cash flow of $-15,771,250, indicating that current operational cash generation is insufficient to cover capital expenditures and working capital requirements, thereby limiting immediate financial flexibility for internal expansion. The margin profile further illustrates this financial pressure, with a gross margin of only 3.1%, an operating margin of -108.2%, and a profit margin of -140.3%, all pointing to intense pricing pressure or high cost of goods sold relative to sales. Regarding liquidity and leverage, the firm holds $38.73M in cash against $23.87M in debt, resulting in a debt-to-equity ratio of 71.90 which suggests a leveraged balance sheet reliant on equity financing or asset appreciation to service obligations. Despite the leverage, the current ratio stands at 3.31, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against immediate solvency risks. Return metrics confirm the impact of these losses, with a return on equity of -86.8% and a return on assets of -34.2%, demonstrating that management has yet to deploy capital efficiently to generate positive returns for shareholders.
Waarderingsbeoordeling
Valuation multiples for Rapid Micro Biosystems reflect its status as a pre-profitability growth company, evidenced by a trailing P/E ratio that is listed as N/A and a forward P/E of -2.57. The divergence between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in an anticipated turnaround in earnings trajectory, though the current negative multiple suggests expected earnings are still negative or near breakeven. The price-to-book ratio is calculated at 2.84, indicating that the market values the company at nearly three times its book value, which suggests a premium assigned to its intangible assets, technology IP, or future growth potential despite current losses. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 2.89 and an EV/EBITDA of -1.83, suggesting that investors are willing to pay a significant multiple of revenue for the company given its specific niche in microbial detection. Price action over the last year shows a 52-week high of $4.94 and a 52-week low of $2.00, meaning the stock trades within a range where the upper bound represents a 147% premium over the lower bound, highlighting the volatility inherent in small-cap healthcare plays. The stock exhibits a beta of 1.60, which signifies that the share price is expected to be 60% more volatile than the broader market, amplifying both potential gains and losses during periods of market fluctuation.
Growth & Income
Revenue growth for the company was robust at 37.3% year-over-year, whereas earnings growth is listed as N/A due to the company's continued net losses. This divergence indicates that while top-line sales are expanding rapidly, the company has not yet achieved the economies of scale necessary to convert that revenue growth into profitability, implying that the path to positive earnings may require further capital investment or cost reductions. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is retained within the business to fund operations and research rather than being distributed to shareholders. The overall growth and income profile characterizes Rapid Micro Biosystems as a high-risk, high-potential candidate that relies entirely on reinvesting its limited cash reserves and raising external capital to fuel expansion, as it offers no current income stream to investors seeking yield.